African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center.

Sézary syndrome (SS) is an aggressive cutaneous T-cell lymphoma with poor survival. We performed a retrospective review of SS patients at Emory University from 1990 to 2020. We collected data on race, clinical characteristics, therapy, and social determinants of health. Clinical endpoints were overall survival (OS) and time to next treatment (TTNT). Univariate association and multivariable analyses were assessed by Cox proportional hazards models. Among 62 patients, 45.2% were AA. The median OS and TTNT were 3.1 years and 6.3 months, respectively, with no difference by race. AA patients had a higher median baseline LDH (360 <i>vs.</i> 232, <i>p</i> = 0.002) and a longer delay in initiation of systemic therapy compared to CC patients (3.17 <i>vs.</i> 2.14 months, <i>p</i> = 0.039), but a shorter commute (&lt;10 miles) and no difference in insurance coverage (<i>p</i> = 0.260). AA patients at an academic center had unique clinical features and treatment patterns, but similar survival to CC SS patients.